全球生物醫藥品市場

本報告提供全球生物醫藥品市場相關調查分析，提供產業分析，市場分析，各地區分析，競爭情形，主要企業等相關的系統性資訊。

第1章 目錄

第2章 摘要整理

第3章 簡介

第4章 市場趨勢

• 主要的發展
• 未來市場預測

第5章 生物醫藥品市場:產業分析

• 推動市場要素
• 阻礙市場要素
• 威脅和機會
• 波特的五力分析

第6章 生物醫藥品市場:市場分析

• 生物醫藥品市場:各產品
• 生物醫藥品市場:各用途

第7章 生物醫藥品市場:各地區分析

• 北美
• 歐洲
• 亞太地區
• 中東·非洲
• 南美

第8章 生物醫藥品市場:競爭情形

• 市場佔有率分析
• M&A分析
• 新產品的銷售

第9章 生物醫藥品市場:企業簡介

• Abbvie Inc.
• Amgen
• Bayer
• Biogen
• Bristol-Myers Squibb
• ELI Lilly and Company
• Johnson and Johnson
• Merck & Co., Inc.
• Novartis AG
• Novo Nordisk
• Pfizer
• Glaxosmithkline PLC
• Sanofi S.A
• 武田藥品工業

Market Overview

The Global Biopharmaceuticals Market is expected to grow at a CAGR of 14.20% during the forecasting period (2021-2028).

Biopharmaceuticals are large and complex molecular drugs that are mainly obtained from proteins and nucleic acids of living organisms such as microorganisms and animal cells also known as transgenic organisms. These drugs are obtained using biotechnology and have high-therapeutic value. Biopharmaceuticals are also known as biologics and biotech drugs and are usually administered by intravenous, subcutaneous, or intramuscular injections and are more efficient than the conventional small molecule drugs. Biopharmaceuticals are an alternative to the previously less effective and sometimes unsafe treatments and offer several benefits. Biopharmaceuticals benefits include highly effective and potent action, fewer side effects, can be tailored according to specific medical requirements of patients and they hold the potential to actually cure diseases at the root level. Biopharmaceuticals have reduced the number of deaths due to cancer and HIV/AIDS in the past decade and have changed the treatment of several chronic diseases, such as diabetes and cardiovascular diseases.

Some of the biopharmaceuticals include monoclonal antibodies, erythropoietin, growth hormones, recombinant proteins, recombinant human insulin, purified proteins, interferon, and vaccines. Recombinant human insulin was amongst the first substances to be approved for therapeutic purpose, and currently, there are nearly 300 biopharmaceutical products which have been approved and are available in the market.

Market Drivers

The major drivers fueling the growth of the market are an increase in the elderly population, the surge in prevalence of chronic diseases such as cancer and diabetes, increase in obesity and sedentary lifestyle among the population and growing acceptance for biopharmaceuticals due to their ability to treat previously untreatable diseases. Furthermore, approval for newer biopharmaceutical products and continuous R&D in this segment is expected to increase the growth of the market.

According to the World Health Organization (WHO), cancer is the second leading cause of death globally and is responsible for an estimated 9.6 million deaths in 2018. About 1 in 6 deaths worldwide, is due to cancer. Moreover, approximately 100 million people in the year 2018 all over the world needed insulin out of which 63 million were obese, including all the people living with Type 1 diabetes and between 10-25% of people with type 2 diabetes. A sedentary lifestyle leads to several chronic diseases thus boosting the market growth.

Biopharmaceuticals hold the potential to cure the disease entirely and not just the symptoms, hence increasing its acceptance. According to the United Nations (UN) statistics, about 65% of the drugs approved in the market in 2017 are based on biotechnology.

Market Restraints

High costs associated with drug development and their threat of failure, challenging development process, and strict regulatory framework are going to restrain the market in the forecast period.

Generally, the development of a biopharmaceutical product takes around 5 to 9 years and costs over $ 100 million. The regulatory framework plays a major role in deriving incentives for investment and establishing sufficient quality and safety for biomedical products. The WHO has set strict approval standards for biopharmaceuticals.

Market Segmentation

The global biopharmaceuticals market is segmented by product as Monoclonal Antibodies, Recombinant growth factors, Purified Proteins, Recombinant Proteins, Recombinant Hormones, Synthetic Immunomodulators, Vaccines, and Recombinant enzymes. Monoclonal antibodies are further segmented as Anti-Cancer Monoclonal Antibodies, Anti-Inflammatory Monoclonal Antibodies, and Other Monoclonal Antibodies. Recombinant growth factors are further segmented as Erythropoietin and Granulocyte Colony Stimulating Factor. Purified Proteins are further segmented as Leukaemia Inhibitory Factor (LIF), P53 Protein and P38 Protein. Recombinant Proteins are further segmented as Serum Albumin, Amyloid Protein, Defensin, Cyclase, Caspase, and Cathepsin. Recombinant Hormones are further segmented as Recombinant Human Growth Hormone (HGH) and Recombinant Insulin. Synthetic Immunomodulators are further segmented as Cytokines, Interferons, Interleukins and Tumour Necrosis Factor (TNF). Vaccines are further segmented as Recombinant Vaccines and Conventional Vaccines. Recombinant enzymes are further segmented as Enterokinase and Transferrin.

By application, the market is segmented as oncology, inflammatory and infectious diseases, autoimmune disorders, metabolic disorders, hormonal disorders, disease prevention, cardiovascular diseases, and neurological diseases.

Monoclonal Antibodies is the emerging technology that is identical to immune cells and represents a copy of the unique parent cell. As the biopharmaceutical market in the US and the rest of the world continues to expand, the sales of monoclonal antibody products have grown from approximately $50 billion in 2010 to almost $90 billion in 2015, an increase by 1.8 times. In 2018, the monoclonal antibodies market segment accounted for a market share of more than 40% of the global biopharmaceutical market.

Anti-cancer monoclonal antibodies help cure cancer more efficiently. Cancer is the largest segment by application and accounts for more than 20% of the market share. According to the World Cancer Fund, cancer is a global health problem responsible for 7.6 million deaths (13% of all deaths) worldwide and is expected to rise to 13.1 million by 2030. Around 49% of the drugs used in cancer treatment were either natural products or their derivatives.

Geographical Analysis

Geographically, the global Biopharmaceuticals market is divided into North America, Europe, South America, Asia-Pacific and the Middle East and Africa.

In North America, the US biopharmaceuticals market accounted for the largest market share of 46%, followed by Canada. The US is the largest free-pricing market globally for pharmaceuticals and has high per capita incomes, a large elderly population and high rates of chronic diseases and drug consumption. According to the Pharmaceutical Research and Manufacturers Association (PhRMA), U.S. firms conduct over half the world's research and development(R&D) in pharmaceuticals and hold the intellectual property rights on most new medicines.

Asia-Pacific is expected to grow at a steady pace of CAGR 8.34% over the period of forecast. The reason being the encouragement of innovation and price reforms in Japan. Supporting government regulations, advanced technological presence, good infrastructural facilities are some of the major factors for the market growth in the region. For instance, Japan government has set up Japan Agency for Medical Research and Development (AMED) to centralize decision making for strategies and budget allocations, and build a one-stop R&D system and to promote R&D among the private sector.

Competitive Analysis

Some of the major market players are: AbbVie Inc., Amgen, Bayer, Biogen, Bristol-Myers Squibb, Merck & Co., Inc., Novartis AG, Novo Nordisk, Pfizer, GlaxoSmithKline PLC, Sanofi S.A., and Takeda Pharmaceuticals.

Roche, Sanofi, AbbVie, Pfizer, and Merck are the top five companies in the market and account for more than 50% of the biopharmaceutical market share. Many of the biopharmaceutical products are in late stages of clinical development. Under huge economic pressures to increase the outputs, pharmaceutical manufacturers have embraced biopharmaceuticals, and have a huge number of products in their pipelines. Out of every 10 biopharmaceutical drugs that enter the clinical phases, only three manage to gain market approval. As of 2017, around 75% of the total products available in the pipeline belong to biopharmaceuticals, providing large scope for the market in the future.

In June 2018, AbbVie announced U.S. FDA Approval of VENCLEXTA (venetoclax tablets) in combination with Rituximab as a fixed duration treatment for Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Patients who have received one prior therapy.

In June 2018, AbbVie partnered with Eisai and its gastrointestinal diseases unit EA Pharma to introduce an auto-injection delivery pen for Humira drug.

In June 2018, Biogen entered an exclusive option agreement to acquire TMS' Phase II asset for acute stroke.

In April 2018, Servier formed an agreement with Shire plc to acquire its oncology business for $2.4 billion.

In April 2018, Biogen and Ionis expanded strategic collaboration to develop drug candidates for a broad range of neurological diseases.

In January 2018, Alder Biopharmaceuticals, Inc developed Eptinezumab, a monoclonal antibody (mAb) preventing calcitonin gene-related peptide (CGRP), which plays a main role in mediating and initiating migraine.

Why purchase the report?

• Visualize the composition of the biopharmaceuticals market across each indication, in terms of type and by type highlighting the key commercial assets and players.

• Identify commercial opportunities in biopharmaceuticals by analyzing trends and co-development deals.

• Excel data sheets with thousands of data points of biopharmaceuticals market- level 4/5 segmentation.

• A PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.

• Product mapping in excel for the key products of all major market players.

Target Audience:

• Medical device companies
• Hospitals and clinics
• Research and consulting firms
• Healthcare associations/institutes
• Venture capitalists
• Government agencies

Table of Contents

1. Global Biopharmaceuticals Market Methodology and Scope

• 1.1. Research methodology
• 1.2. Scope of the Report

2. Global Biopharmaceuticals Market Definition and Overview

3. Global Biopharmaceuticals Market - Executive Summary

• 3.1. Market Snippet by Product Type
• 3.2. Market Snippet by Application
• 3.3. Market Snippet by Organism
• 3.4. Market Snippet by Region

4. Global Biopharmaceuticals Market - Market Dynamics

• 4.1. Market Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. The ability of biopharmaceuticals to treat previously untreatable diseases
    • 4.1.1.2. Increased uptake of biopharmaceuticals
    • 4.1.1.3. Increasing new product development
  • 4.1.2. Restraints
    • 4.1.2.1. Challenging development process
    • 4.1.2.2. Strict regulatory framework
• 4.2. Opportunity
• 4.3. Impact Analysis

5. Global Biopharmaceuticals Market - Industry Analysis

• 5.1. Porter's Five Force Analysis
• 5.2. Regulatory Analysis
• 5.3. Supply Chain Analysis
• 5.4. Epidemiology

6. Global Biopharmaceuticals Market - By COVID-19 Analysis

• 6.1. Analysis of Covid-19 on the Market*
  • 6.1.1. Before COVID-19 Market Scenario
  • 6.1.2. Present COVID-19 Market Scenario
  • 6.1.3. After COVID-19 or Future Scenario
• 6.2. Pricing Dynamics Amid Covid-19
• 6.3. Demand-Supply Spectrum
• 6.4. Government Initiatives Related to the Market During Pandemic
• 6.5. Manufacturers Strategic Initiatives
• 6.6. Conclusion

7. Global Biopharmaceuticals Market - By Product Type

• 7.1. Introduction
  • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
  • 7.1.2. Market Attractiveness Index, By Product Type
• 7.2. Monoclonal Antibodies*
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis, US$ Million, 2019-2028 and Y-o-Y Growth Analysis (%), 2021-2028
  • 7.2.3. Anti-Cancer Monoclonal Antibodies
  • 7.2.4. Anti-Inflammatory Monoclonal Antibodies
  • 7.2.5. Other Monoclonal Antibodies
• 7.3. Recombinant Growth Factors
  • 7.3.1. Introduction
  • 7.3.2. Market Size Analysis, US$ Million, 2019-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 7.3.3. Erythroprotein
  • 7.3.4. Granulocyte Colony Stimulating Factor
• 7.4. Purified Proteins
  • 7.4.1. Introduction
  • 7.4.2. Market Size Analysis, US$ Million, 2019-2028 and Y-o-Y Growth Analysis (%), 2021-2028
  • 7.4.3. Leukemia Inhibitory Factor (LIF)
  • 7.4.4. P53 Protein
  • 7.4.5. P38 Protein
• 7.5. Recombinant Proteins
  • 7.5.1. Introduction
  • 7.5.2. Market Size Analysis, US$ Million, 2019-2028 and Y-o-Y Growth Analysis (%), 2021-2028
    • 7.5.2.1. Serum Albumin
    • 7.5.2.2. Amyloid Protein
    • 7.5.2.3. Defensin
    • 7.5.2.4. Cyclase
    • 7.5.2.5. Caspase
    • 7.5.2.6. Cathepsin
• 7.6. Recombinant Hormones
  • 7.6.1. Introduction
  • 7.6.2. Market Market Size Analysis, US$ Million, 2019-2028 and Y-o-Y Growth Analysis (%), 2021-2028
    • 7.6.2.1. Recombinant Human Growth Hormones (HGH)
    • 7.6.2.2. Recombinant Insulin
• 7.7. Synthetic Immunomodulators
  • 7.7.1. Introduction
  • 7.7.2. Market Size Analysis, US$ Million, 2019-2028 and Y-o-Y Growth Analysis (%), 2021-2028
    • 7.7.2.1. Cytokines, Interferons, Interleukins
    • 7.7.2.2. Tumor Necrosis Factor (TNF)
• 7.8. Vaccines
  • 7.8.1. Introduction
  • 7.8.2. Market Size Analysis, US$ Million, 2019-2028 and Y-o-Y Growth Analysis (%), 2021-2028
  • 7.8.3. Recombinant vaccines
  • 7.8.4. Conventional Vaccines
• 7.9. Recombinant Enzymes
  • 7.9.1. Introduction
  • 7.9.2. Market Size Analysis, US$ Million, 2019-2028 and Y-o-Y Growth Analysis (%), 2021-2028
    • 7.9.2.1. Enterokinase
    • 7.9.2.2. Transferrin

8. Global Biopharmaceuticals Market - By Application

• 8.1. Introduction
  • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
  • 8.1.2. Market Attractiveness Index, By Application
• 8.2. Oncology*
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis, US$ Million, 2019-2028 and Y-o-Y Growth Analysis (%), 2021-2028
• 8.3. Inflammatory and Infectious Diseases
• 8.4. Autoimmune Disorders
• 8.5. Metabolic Disorders
• 8.6. Hormonal Disorders
• 8.7. Cardiovascular Diseases
• 8.8. Neurological Diseases
• 8.9. Others

9. Global Biopharmaceuticals Market - By Organism

• 9.1. Introduction
  • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Organism
  • 9.1.2. Market Attractiveness Index, By Organism
• 9.2. Microorganism*
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis, US$ Million, 2019-2028 and Y-o-Y Growth Analysis (%), 2021-2028
• 9.3. Mammalian Cell
• 9.4. Animal Fluid
• 9.5. Organs and Tissues
• 9.6. Genetically Modified Cells
• 9.7. Plant Cells

10. Global Biopharmaceuticals Market - By Region

• 10.1. Introduction
  • 10.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
  • 10.1.2. Market Attractiveness Index, By Region
• 10.2. North America
  • 10.2.1. Introduction
  • 10.2.2. Key Region-Specific Dynamics
  • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
  • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
  • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Organism
  • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 10.2.6.1. U.S.
    • 10.2.6.2. Canada
    • 10.2.6.3. Mexico
• 10.3. South America
  • 10.3.1. Introduction
  • 10.3.2. Key Region-Specific Dynamics
  • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
  • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
  • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Organism
  • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 10.3.6.1. Brazil
    • 10.3.6.2. Argentina
    • 10.3.6.3. Rest of South America
• 10.4. Europe
  • 10.4.1. Introduction
  • 10.4.2. Key Region-Specific Dynamics
  • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
  • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
  • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Organism
  • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 10.4.6.1. Germany
    • 10.4.6.2. U.K.
    • 10.4.6.3. France
    • 10.4.6.4. Spain
    • 10.4.6.5. Italy
    • 10.4.6.6. Rest of Europe
• 10.5. Asia-Pacific
  • 10.5.1. Introduction
  • 10.5.2. Key Region-Specific Dynamics
  • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
  • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
  • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Organism
  • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 10.5.6.1. China
    • 10.5.6.2. India
    • 10.5.6.3. Japan
    • 10.5.6.4. Australia
    • 10.5.6.5. Rest of Asia-Pacific
• 10.6. Middle East & Africa
  • 10.6.1. Introduction
  • 10.6.2. Key Region-Specific Dynamics
  • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
  • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
  • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Organism

11. Global Biopharmaceuticals Market - Competitive Landscape

• 11.1. Competitive Scenario
• 11.2. Competitor Strategy Analysis
• 11.3. Comparative Product Portfolio Analysis
• 11.4. Market Positioning/Share Analysis
• 11.5. Mergers and Acquisitions Analysis

12. Global Biopharmaceuticals Market - Company Profiles

• 12.1. AbbVie Inc.*
  • 12.1.1. Company Overview
  • 12.1.2. Product Portfolio and Description
  • 12.1.3. Key Highlights
  • 12.1.4. Financial Overview
• 12.2. Amgen
• 12.3. Bayer
• 12.4. Biogen
• 12.5. Bristol-Myers Squibb
• 12.6. ELI Lilly and Company
• 12.7. Johnson And Johnson
• 12.8. Merck & Co., Inc.
• 12.9. Novartis AG
• 12.10. Novo Nordisk
• 12.11. Pfizer
• 12.12. GlaxoSmithKline PLC
• 12.13. Sanofi S.A.
• 12.14. Takeda Pharmaceuticals

13. Global Biopharmaceuticals Market - DataM

• 13.1. Appendix
• 13.2. About Us and Services
• 13.3. Contact Us